Literature DB >> 9564665

Human issues and medical economics of endometriosis. Three- vs. six-month GnRH-agonist therapy.

W L Heinrichs1, M R Henzl.   

Abstract

OBJECTIVE: To project the efficacy and economic consequence of short-term intranasal gonadotropin-releasing hormone agonist (GnRH-a) for diagnosis of and therapy for endometriosis. STUDY
DESIGN: Multicenter, placebo-controlled clinical trials of GnRH-a comparing three vs. six months of treatment, three months of retreatment and three months of postoperative treatment for the symptoms and signs of laparoscopically diagnosed endometriosis.
RESULTS: The reduction in symptoms and signs of endometriosis was similar at the end of three months to the relief at six months. Retreatment was as effective as initial treatment, and the return of symptoms after laparoscopic surgery plus postoperative treatment for three months was delayed by approximately 18 months as compared to surgery alone. The projected charges for the surgical approaches (laparoscopy or minilaparoscopy) to diagnosis and therapy were 50-60% greater than those for the medical approach.
CONCLUSION: GnRH-a administration for three months could be a cost-effective approach to the presumptive diagnosis and treatment of endometriosis among women with chronic pelvic pain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564665

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

1.  Patients' report on how endometriosis affects health, work, and daily life.

Authors:  Jessica Fourquet; Xin Gao; Diego Zavala; Juan C Orengo; Sonia Abac; Abigail Ruiz; Joaquín Laboy; Idhaliz Flores
Journal:  Fertil Steril       Date:  2010-05-01       Impact factor: 7.329

2.  Dienogest in long-term treatment of endometriosis.

Authors:  Adolf E Schindler
Journal:  Int J Womens Health       Date:  2011-07-06

3.  Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone.

Authors:  Sanjay K Agarwal; AnnaMarie Daniels; Steven R Drosman; Laurence Udoff; Warren G Foster; Malcolm C Pike; Darcy V Spicer; John R Daniels
Journal:  Biomed Res Int       Date:  2015-12-31       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.